Real-world safety and effectiveness of rotigotine in patients with Parkinson’s disease: analysis of a post-marketing surveillance study in Japan

References

• Zigmond MJ, Burke RE, et al. Pathophysiology of Parkinson's disease. In: Davis KL, Charney D, Coyle JT, editors. Neuropsychopharmacology: The fifth generation of progress. Philadelphia (PA): Lippincott Williams & Wilkins; 2002. p. 1781–1793. Available from https://acnp.org/wp-content/uploads/2017/11/C123_1781-1794.pdf.
   Google Scholar
• Wirdefeldt K, Adami HO, Cole P, et al. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011;26 Suppl 1:S1–S58.
   PubMed Web of Science ®Google Scholar
• Yamawaki M, Kusumi M, Kowa H, et al. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology. 2009;32(4):263–269.
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour and Welfare. [Summary of statistical study on patients 2017]. https://www.e-stat.go.jp/stat-search/files?page=2&layout=dataset&toukei=00450022&tstat=000001031167&stat_infid=000031790685 [Japanese].
   Google Scholar
• Schapira AH. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005;76(11):1472–1478.
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, et al. The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev. 2013;65(1):171–222.
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;68(6):685–690.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–1491.
   PubMed Web of Science ®Google Scholar
• Group PS. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284(15):1931–1938.
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K, the Ropinirole Study Group, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology. 1998;51(4):1057–1062.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Neurology. [Practical guideline for Parkinson's Disease 2018]. https://www.neurology-jp.org/guidelinem/parkinson_2018.html (Japanese).
   Google Scholar
• Otsuka Pharmaceutical Co., Ltd. [Neupro® Patch Interview form, revised March 2016 (version 7)].
   Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34(4):966–978.
   PubMed Web of Science ®Google Scholar
• Hatano T, Hattori N. [Questionnaire survey on adherence in Parkinson’s disease patients]. Pharma Medica. 2013;31(5):101–107 (Japanese).
   Google Scholar
• Mizuno Y, Nomoto M, Kondo T, Rotigotine Trial Group, et al. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Mov Disord. 2013;28(10):1447–1450.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Nomoto M, Hasegawa K, Rotigotine Trial Group, et al. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. Parkinsonism Relat Disord. 2014;20(12):1388–1393.
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–2404.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262–1267.
   PubMed Web of Science ®Google Scholar
• Tomlinson LC, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–2653.
   PubMed Web of Science ®Google Scholar
• Nomoto M, Iwaki H, Kondo H, et al. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol. 2018; 265(2):253–265.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tan LC. Revisiting the medical management of Parkinson's disease: Levodopa versus dopamine agonist. Curr Neuropharmacol. 2016;14(4):356–363.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline plc. [ReQuip CR Tablets 0.25 mg, 1 mg, 2 mg Interview form_Oct.2019] [Japanese].
   Google Scholar
• Nippon Boehringer Ingelheim Co., Ltd. [Domin® Tablets 0.4 Interview form_Aug.2019] [Japanese].
   Google Scholar
• Pfizer Inc. [Cabasar® Tablets 0.25 mg, 1.0 mg Interview form_Sep.2019] [Japanese].
   Google Scholar
• Nippon Boehringer Ingelheim Co., Ltd. [BI Sifrol® Tablets 0.125 mg, 0.5 mg Interview form_Aug.2019] [Japanese].
   Google Scholar
• Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol. 2004;58(6):601–608.
   PubMed Web of Science ®Google Scholar
• Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135–143.
   PubMed Web of Science ®Google Scholar
• Day JC, Fibiger HC. Dopaminergic regulation of septohippocampal cholinergic neurons. J Neurochem. 1994;63(6):2086–2092.
   PubMed Web of Science ®Google Scholar
• Sohya K, O'Hashi K, Toma H, et al. Different effects of rotigotine and ropinirole on cholinergic transmission in the mouse medial prefrontal cortex. Psychogeriatrics. 2017;17(6):502–503.
   PubMed Web of Science ®Google Scholar
• Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1–14.
   PubMed Web of Science ®Google Scholar